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Abstract
The focal adhesion kinase, FAK, is an important component of an integrin-dependent signaling pathway, which functions
to transmit signals from the extracellular matrix into the cytoplasm. FAK is an essential gene product, since the fak3/3
mouse exhibits embryonic lethality. A number of important biological processes, including cell motility and cell survival, are
controlled by integrin-dependent signals and FAK has been implicated in regulating these processes. This review will focus
upon recent findings providing insight into the mechanisms by which FAK transmits biochemical signals and elicits
biological effects. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Overview
The focal adhesion kinase, FAK, is a cytoplasmic
protein tyrosine kinase that discretely localizes to
regions of the cell that attach to the extracellular
matrix, called focal adhesions [1^4]. Many stimuli
can induce tyrosine phosphorylation and activation
of the catalytic activity of FAK, including growth
factors, neuropeptides, reagents that stimulate
G-protein coupled receptors and mechanical stimuli.
However, the major mode of regulation is via integ-
rin-dependent adhesion to the extracellular matrix
and FAK is an integral component of the integrin-
signaling pathway.
The biological functions of FAK have been ex-
plored by perturbing endogenous FAK signaling
and by overexpression of FAK. Inhibition of endog-
enous FAK signaling results in reduced motility and
in some cases induces cell death [5,6]. Conversely,
enhancing FAK signaling by exogenous expression
increases cell motility and can promote cell survival
in the absence of a signal from the extracellular ma-
trix [7,8]. Thus, FAK has been implicated in control-
ling cell motility and transmitting a cell survival sig-
nal from the extracellular matrix. Given the
important role of FAK in the control of these fun-
damental biological properties, there is considerable
interest in the mechanisms by which FAK signals.
FAK contains large N- and C-terminal domains
that £ank the catalytic domain (see Fig. 1). There
are six sites of tyrosine phosphorylation. The major
site of autophosphorylation, tyrosine 397, lies just
upstream of the kinase domain and is a docking
site for the SH2 domains of a number of proteins
0167-4889 / 01 / $ ^ see front matter ß 2001 Elsevier Science B.V. All rights reserved.
PII: S 0 1 6 7 - 4 8 8 9 ( 0 1 ) 0 0 1 2 3 - 9
* Fax: +1-919-966-1856.
E-mail address: crispy4@med.unc.edu (M.D. Schaller).
BBAMCR 14775 17-7-01 Cyaan Magenta Geel Zwart
Biochimica et Biophysica Acta 1540 (2001) 1^21
www.bba-direct.com
including the Src family of tyrosine kinases [9]. The
¢ve other sites of phosphorylation on FAK are likely
phosphorylated by bound Src kinases [10]. Two
phosphorylation sites in the activation loop of the
catalytic domain, tyrosines 576 and 577, are regula-
tory sites of phosphorylation that enhance catalytic
activity. Phosphorylation of tyrosine 925, located in
the C-terminal domain of FAK, creates a binding
site for the SH2 domain of Grb2 and presents one
mechanism of activation of the Ras/MAPK pathway
by FAK [11]. Several proline-rich sequences in the
C-terminal domain of FAK serve as binding sites
for SH3 domain containing proteins and mediate
binding to p130cas and GRAF [12,13].
The focal adhesion targeting (FAT) sequence of
FAK is located at the C-terminus and mediates the
localization of FAK to focal adhesions [14]. This
region also contains binding sites for two focal adhe-
sion-associated proteins, paxillin and talin [15,16].
The precise mechanism of targeting is not estab-
lished. The C-terminal noncatalytic domain of
FAK, called FRNK, is autonomously expressed in
some cell types and is frequently used as a dominant
negative FAK variant.
FAK has been implicated in directing the tyrosine
phosphorylation of several substrates, including
p130cas and paxillin [7,17,18]. These substrates might
be directly phosphorylated by FAK or indirectly by
Src, which has been recruited into complex with
FAK. Upon phosphorylation of both p130cas and
paxillin, adaptor proteins like Crk and Nck can be
recruited into complex with these proteins. These
adaptor proteins bring other signaling proteins,
e.g., C3G, into the complex to facilitate the genera-
tion of downstream signals. In addition to tyrosine
phosphorylation of downstream substrates, the re-
cruitment of adaptor/signaling molecules, like Grb2
and PI3K, into complex with FAK is also a very
important mechanism of signaling [11,19].
A second PTK, that shares structural and se-
quence homology with FAK is Pyk2/CAKL/
RAFTK/CadTK/FAK2. CAKL binds to a number
of proteins in common with FAK including Src fam-
ily kinases and cytoskeletal proteins like paxillin. The
subcellular localization of CAKL is variable but is
generally described as di¡usely cytoplasmic. CAKL
is regulated by a number of stimuli that elevate cy-
toplasmic levels of calcium. Thus FAK and CAKL
respond to di¡erent stimuli, but may engage similar
cellular components to transmit downstream signals.
Since CAKL has recently been reviewed [1,20], this
topic will not be addressed further in this review.
Fig. 1. Domain structure of FAK. The organization of the N-terminal, kinase and C-terminal domains are shown. The N-terminus in-
teracts with integrins and growth factor receptors. The FERM domain, regions of homology with band 4.1 and ezrin/radixin/moesin
proteins, is indicated by black bars in the N-terminus. The C-terminal focal adhesion targeting (FAT) sequence, which contains paxil-
lin and talin binding sites, is also shown. Proline rich sequences (P), sites of tyrosine phosphorylation (Y) and a caspase cleavage site
(D) are illustrated. The domain structure of FRNK, an autonomously expressed FAK variant that can function as a dominant nega-
tive mutant, is also shown.
BBAMCR 14775 17-7-01 Cyaan Magenta Geel Zwart
M.D. Schaller / Biochimica et Biophysica Acta 1540 (2001) 1^212
2. FAK: sequence conservation and functions of
domains
2.1. Evolutionary conservation of FAK sequence and
function
The Drosophila homologue of FAK, called
DFak56, was recently isolated and exhibits approx-
imately 33% amino acid identity with human FAK
[21^23]. DFak56 exhibits the same organization of
domains as FAK, with a central catalytic domain
£anked by N- and C-terminal noncatalytic domains
(see Fig. 2). However, DFak56 contains a large
C-terminal extension beyond the C-terminal FAT
sequence of FAK. DFak56 shares a number of bio-
logical properties with FAK including subcellular
localization to focal adhesions and cell adhesion-
dependent regulation of tyrosine phosphorylation
[21^23].
Naturally, the tyrosine kinase domain is most
highly conserved between DFak56 and human
FAK exhibiting 63% identity. The FAT sequence is
also highly conserved showing 47% identity, whereas
the N-terminal domain and the region between the
catalytic domain and FAT sequence of DFak56 are
only 32% and 31% identical to human FAK. Not
surprisingly, the major autophosphorylation site is
conserved in DFak56, as are the regulatory tyrosine
residues in the catalytic domain. Although DFak56
contains a tyrosine residue corresponding to tyrosine
925 in human FAK, the £anking residues suggest
that DFak56 does not bind to Grb2 via this site.
The ¢rst proline-rich sequence in the C-terminal do-
main of FAK, which is the major p130cas binding
site, is conserved in DFak56, but the second proline
sequence in the C-terminal domain, which is the ma-
jor GRAF binding site, is not conserved.
It is anticipated that FAK functions in integrin
signaling in Drosophila. This postulate remains to
be rigorously tested, but initial results are consistent
with this hypothesis. L integrin defects in the Droso-
phila wing cause blisters to form. Similarly, overex-
pression of DFak56 in the wing induces blisters [22].
However, the most exciting prospect from this obser-
vation is that DFak56 overexpression induces a read-
ily scored phenotype in £ies. This system will allow
an analysis of genetic interactions between DFak56
and other genes implicated in integrin signaling. Fur-
ther, this model system may be modi¢ed as a genetic
screen for mutations that result in suppression of the
phenotype and thus facilitating the identi¢cation of
new genes that may function in FAK signaling.
2.2. The N-terminal domain of FAK
The N-terminal domain of FAK exhibits sequence
homology with the band 4.1 protein/ERM (ezrin,
radixin and moesin) proteins within a region known
as the FERM domain [24] [25]. This homology is
likely to be signi¢cant for FAK function, since it is
Fig. 2. Sequence homology between human and Drosophila FAK sequences. A schematic illustration of human FAK and Drosophila
FAK, DFak56, is shown. Black bars denote the N-terminal FERM domain. The kinase domain, FAT sequence, major tyrosine phos-
phorylation sites (Y) and proline-rich sequences (P) are indicated. The numbers re£ect the percentage of amino acid identity between
the di¡erent domains of human and Drosophila FAK. The percentage of identical amino acids in the FERM domains is indicated be-
low the cartoon of Drosophila FAK.
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highly conserved evolutionarily. Whereas the N-ter-
minal domains of DFak56 and human FAK are only
32% identical, sequences within the FERM domain
exhibit 49% identity (see Fig. 2). The FERM do-
mains of talin and the ERM proteins mediate inter-
actions with the cytoplasmic domains of transmem-
brane receptors [26^29]. While the function of the
N-terminus of FAK has not been de¢nitively estab-
lished, similar functions have been proposed.
The ¢rst function proposed for the N-terminal do-
main of FAK was binding to the cytoplasmic tails of
L integrin subunits, since FAK could complex with
peptides mimicking L integrin cytoplasmic domains
in vitro [30]. FAK was shown to co-cluster with in-
tegrins upon capping with integrin antibodies under
conditions where most focal adhesion-associated pro-
teins, most notably paxillin and talin, failed to co-
cluster [31]. Further, FAK and L1 integrin subunits
were recently reported to coimmunoprecipitate and
thus may associate in vivo [32,33]. However, the
function of this interaction remains to be established.
This interaction is clearly dispensable for localization
of FAK and mutational analyses of both FAK and
the L3 integrin subunit demonstrate that this inter-
action is not required for cell adhesion dependent
tyrosine phosphorylation of FAK [34,35].
A number of reports have suggested that FAK
functions downstream of growth factor receptors,
since tyrosine phosphorylation of FAK is stimulated
by treatment of cells with growth factors. Recent
evidence, which will be discussed below, has impli-
cated FAK as an important element in coordinating
biochemical signals and biological responses follow-
ing stimulation of growth factor receptors and integ-
rins. A recent study has suggested a mechanism for
linkage of FAK to growth factor receptor signaling.
In several cell systems FAK was found to coimmu-
noprecipitate with the EGF receptor or the PDGF
receptor following stimulation with their cognate li-
gand [36]. The N-terminal domain of FAK mediates
this interaction and mutants of FAK that exhibit
reduced receptor binding are impaired in their ability
to coordinate this signal into a biological response
[36]. Perhaps related to the observed interaction of
FAK with the EGF and PDGF receptors is the re-
cent ¢nding that FAK can coimmunoprecipitate with
a number of other receptor tyrosine kinases including
ErbB2, ErbB3, the IGF1 receptor, and Eph2A [37^
40]. Although these are very intriguing ¢ndings, there
are still a number of outstanding issues regarding
these observation. It remains to be established
whether the interaction between FAK and the
EGF/PDGF receptors is direct or indirect and the
molecular details of the binding site remain to be
elucidated. Further, the molecular mechanism of
the interaction of FAK with the other receptor tyro-
sine kinases has not been determined. It will be in-
teresting to see if FAK associates with these other
receptors through its N-terminal domain and if the
FERM homology domain mediates these interac-
tions.
2.3. Tyrosine 397: site of autophosphorylation and
docking site for SH2 domains
The major site of autophosphorylation of FAK is
tyrosine 397, a residue that lies immediately N-termi-
nal to the catalytic domain. This residue is vital for
the biochemical and biological functions of FAK.
Although Src was the ¢rst SH2 domain-containing
protein found to bind to the autophosphorylation
site of FAK, recent evidence demonstrates that the
SH2 domains of PI3-kinase, PLCQ and Grb7 also
bind to the FAK autophosphorylation site [41^43].
Shc also associates with FAK and tyrosine 397 is
required for binding the Shc SH2 domain, but the
binding site for Shc remains to be conclusively iden-
ti¢ed [44]. Thus there are at least four distinct signal-
ing molecules recruited into complex with a single
docking site on FAK (see Fig. 3). It is not possible
for multiple SH2 domain-containing proteins to si-
multaneously dock with a single tyrosine phosphor-
ylated binding site. Therefore autophosphorylation
must promote the assembly of a number of distinct
FAK containing signaling complexes. These individ-
ual complexes could be assembled into higher order
complexes in focal adhesions, facilitating the colocal-
ization of a number of distinct signaling molecules.
This might provide a mechanism for coordinating
signaling through multiple pathways. Alternatively,
the colocalization of complexes may promote further
interplay between FAK-binding partners. For exam-
ple, recruitment of PI3-kinase and PLCQ into com-
plex with FAK could facility the generation of
PI(3,4,5)P3 by PI3-kinase, which then serves as a
docking site for the PH domain of PLCQ.
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2.4. The C-terminal domain and focal adhesion
targeting
The correct subcellular localization of FAK is es-
sential for its function. Mutants of FAK that fail to
localize to focal adhesions are not regulated in re-
sponse to cell adhesion [34,45]. Further, displacement
of endogenous FAK from focal adhesions by over-
expression of the C-terminal non-catalytic domain of
FAK, inhibits tyrosine phosphorylation of FAK and
impairs its biological functions [46^50]. Given the
importance of this region of FAK for its function,
there is considerable interest in elucidating the mech-
anism of focal adhesion targeting.
Two focal adhesion-associated proteins, paxillin
and talin, have been identi¢ed as binding partners
for the FAT sequence of FAK and each has been
proposed as the mediator of FAK localization. The
N-terminus of paxillin contains ¢ve copies of a motif,
the LD motif, that functions in mediating protein^
protein interactions [51]. Two of these motifs mediate
the interaction of paxillin with FAK and are also
involved in binding vinculin [52,53]. In the FAT
sequence of FAK are two short, noncontiguous se-
quences that exhibit sequence homology with the re-
gion of vinculin that binds paxillin [54]. Mutation of
residues within these sequences, PBS1 (for paxillin
binding site 1) and PBS2 (paxillin binding site 2),
disrupt paxillin binding and focal adhesion targeting
[54]. These results suggest that binding to paxillin
mediates targeting of FAK to focal adhesions. How-
ever, other evidence suggests that this may not be the
case. Although there is sequence conservation of
PBS1 and PBS2 in Drosophila FAK, there are resi-
dues in each site that have been implicated in paxillin
binding but are not conserved in DFak56 [21^23].
While the Drosophila homologue of paxillin might
contain complementary mutations to preserve the in-
teraction with these altered FAK sequences, it is also
possible that other FAK sequences play an impor-
tant role in paxillin binding. Additional mutational
analysis of FAK has revealed other residues outside
of PBS1 and PBS2 that are also essential for paxillin
binding [45]. The most signi¢cant ¢nding was that a
number of FAK mutants that cannot bind paxillin
could still localize to focal adhesions [16,45]. Thus,
paxillin binding is not essential for focal adhesion
localization of FAK. However, it may be noteworthy
that all of the mutants described to date that fail to
target to focal adhesions are also unable to bind to
paxillin [45,54].
Talin has also been suggested to target FAK to
Fig. 3. Multiple signaling proteins dock at Tyrosine 397 of FAK. The single major autophosphorylation site of FAK binds to at least
four di¡erent SH2 domain containing signaling molecules: Src, PI3-kinase, PLCQ and Grb7. Src and PI3-kinase function in the regula-
tion of motility, as may Grb7. Some of these proteins also function in transmitting a cell survival signal, but the critical FAK-binding
partners have not been absolutely identi¢ed.
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focal adhesions. This conclusion is based upon the
observation that CAKL, which is generally di¡usely
localized in the cell, fails to coimmunoprecipitate
with talin, whereas the focal adhesion-associated
FAK can coimmunoprecipitate with talin [55]. How-
ever, it is also possible that CAKL fails to coimmu-
noprecipitate with talin because it is localized di¡er-
ently in the cell, i.e., the talin-binding activity of
CAKL has not been assessed in vitro. Further, the
C-terminal domain of CAKL can localize to focal
adhesions when expressed autonomously [56,57]. Fi-
nally, the subcellular localization of some deletion
mutants of FAK does not correlate with talin-bind-
ing activity [15]. Thus talin binding also fails to ex-
plain the ability of FAK to target to focal adhesions.
Is it possible to reconcile these data and formulate
a hypothetical mechanism for focal adhesion target-
ing of FAK? Perhaps there is another FAK-binding
partner that has not been identi¢ed and this un-
known protein functions to target FAK to focal ad-
hesions. More likely, there is more than one inde-
pendent mechanism for targeting FAK to focal
adhesions, e.g., via talin binding or via paxillin bind-
ing. Thus paxillin-binding mutants may target to fo-
cal adhesions by interacting with talin, and paxillin
may mediate the focal adhesion localization of FAK
mutants defective for talin binding. This theory re-
mains to be tested, but could potentially resolve the
discrepancy in the literature.
One other intriguing observation is that the C-ter-
minal domain of FAK can be expressed as an auton-
omous protein, FRNK. The expression of endoge-
nous FRNK was ¢rst observed in primary CE cells
[58]. Two major transcripts are detected in CE cells,
a 4.5 kb mRNA that encodes FAK and a 2.5 kb
mRNA that encodes FRNK [58]. The shorter
mRNA is transcribed from an alternate promoter
located within an intron of the FAK gene [59].
Whereas FAK is broadly expressed in cells and tis-
sues, FRNK expression is quite restricted. FRNK
expression has been detected in avian and murine
lung tissue and in murine smooth muscle, most no-
tably in the smooth muscle of the vasculature [59,60].
Interestingly, FRNK expression is elevated in arterial
smooth muscle following vascular injury [60]. FRNK
has been utilized as a dominant negative mutant to
inhibit FAK signaling in a number of studies (e.g.,
see [46,47,61,62]). Exogenous expression of FRNK
may inhibit endogenous FAK by displacing FAK
from focal adhesions and/or titrating critical signal-
ing partners away from FAK. The function of en-
dogenous FRNK has not been established. FRNK
may function as a natural competitive inhibitor of
FAK or FRNK might augment a noncatalytic func-
tion of FAK, e.g., by providing a focal adhesion
docking site for a FAK/FRNK-binding partner.
3. Activation of FAK and Src
3.1. How is FAK activated after integrin stimulation?
The co-localization of FAK with integrins in focal
adhesions is a prerequisite for cell adhesion-depen-
dent activation of FAK signaling. Mutants of FAK
that are unable to localize to focal adhesions fail to
become tyrosine phosphorylated in response to cell
adhesion to ¢bronectin [34,45]. Additional evidence
for the importance of localization in signaling comes
from the analysis of CAKL. The subcellular localiza-
tion of CAKL is generally di¡use and tyrosine phos-
phorylation of CAKL is weakly stimulated upon cell
adhesion [55,56,63]. Chimeric FAK/CAKL proteins,
in which the FAT sequence of FAK is substituted for
the corresponding sequence of CAKL, very e⁄ciently
target to focal adhesions and become prominently
tyrosine phosphorylated in response to cell adhesion
[55,63]. These ¢ndings demonstrate that localization
is a critical requirement for regulation of FAK by
cell adhesion.
The actin cytoskeleton is also essential for tyrosine
phosphorylation of FAK, since cytochalasin D abol-
ishes tyrosine phosphorylation of FAK in response
to many stimuli, including integrin-dependent cell
adhesion [64,65]. Members of the Rho family of
GTP-binding proteins are key regulators of the actin
cytoskeleton, and Rho itself promotes contractility
and the formation of stress ¢bers and focal adhesions
[66]. Several lines of evidence suggest that activation
of Rho induces tyrosine phosphorylation of FAK,
whereas inhibition of Rho blocks the tyrosine phos-
phorylation of FAK in response to certain stimuli
[67^70]. These data suggest tyrosine phosphorylation
of FAK may be controlled by Rho-dependent alter-
ations of the actin cytoskeleton. The activity of Rho
has been measured and found to transiently decline
BBAMCR 14775 17-7-01 Cyaan Magenta Geel Zwart
M.D. Schaller / Biochimica et Biophysica Acta 1540 (2001) 1^216
upon cell adhesion and then increase above basal
levels observed in cells in suspension [71]. The ¢nding
that Rho activity decreases upon adhesion to ¢bro-
nectin seems at odds with the hypothesis that Rho
stimulates tyrosine phosphorylation of FAK, since
FAK tyrosine phosphorylation increases upon cell
adhesion to ¢bronectin. However, the reduction in
Rho activity is only several-fold and the residual ac-
tive Rho could still potentially function to induce
tyrosine phosphorylation of FAK upon cell adhe-
sion. For example, localization of the active subpop-
ulation of Rho to sites of adhesion could promote
contractility and localized clustering of cytoskeletal
components, including FAK, leading to FAK auto-
phosphorylation and activation of FAK signaling
pathways.
An important event in the enzymatic activation of
FAK is phosphorylation of the tyrosine residues in
the activation loop. These residues are not sites of
autophosphorylation of FAK, but are phosphorylat-
ed by Src family kinases [10]. Pharmacological inhib-
itors of Src have been used to assess the role of Src in
tyrosine phosphorylation of FAK in several signaling
scenarios. Inhibition of Src signaling impairs tyrosine
phosphorylation of tyrosine residue 925 of FAK fol-
lowing adhesion to ¢bronectin [65]. Inhibition of Src
also inhibits tyrosine phosphorylation of FAK, spe-
ci¢cally at activation loop residues, in response to
bombesin stimulation of Swiss 3T3 cells [72]. Fur-
ther, genetic analyses have also implicated Src in
the tyrosine phosphorylation of FAK following in-
tegrin-dependent cell adhesion. Src3/3 ¢broblasts
are slightly defective and ¢broblasts de¢cient for
the src, fyn and yes genes exhibit a dramatic defect
in the cell adhesion-dependent tyrosine phosphoryla-
tion of FAK [73,74]. Analysis of FAK tyrosine phos-
phorylation in these cells using phospho-speci¢c anti-
bodies has not been reported; hence the role of Src
in promoting phosphorylation of distinct tyrosine
residues in FAK has not been addressed genetically.
Nevertheless, these results support the hypothesis
that Src is required for maximum induction of
FAK tyrosine phosphorylation in response to cell
adhesion.
Src is proposed to bind to the autophosphoryla-
tion site of FAK to facilitate Src-dependent phos-
phorylation of other tyrosine residues on FAK.
However, there is evidence from src-transformed ¢-
broblasts that activated Src mutants can phosphory-
late the FAK 397F mutant, which is defective for Src
binding [75,76]. The presence of a Src SH3 binding
site in FAK complicates this interpretation since
there might still be a weak interaction [77]. These
results suggest that in the context of src-transformed
cells, Src does not have to stably dock with FAK to
induce its tyrosine phosphorylation. In terms of in-
tegrin-dependent signaling in ¢broblasts, this ques-
tion has been addressed by characterizing FAK
mutants using phospho-speci¢c antibodies. An
autophosphorylation site mutant of FAK, which
fails to associate with Src, exhibits a very dramatic
reduction in phosphorylation of activation loop res-
idues [76]. This observation suggests that in response
to cell adhesion, the association of Src with FAK is
required for Src-dependent tyrosine phosphorylation
of the activation loop of FAK. A FAK mutant with
phenylalanine substitutions for the activation loop
sites of tyrosine phosphorylation shows substantial
tyrosine phosphorylation of the major autophos-
phorylation site of FAK, albeit slightly reduced
[76]. This suggests that the cell adhesion-dependent
tyrosine phosphorylation of the autophosphorylation
site of FAK occurs independently of activation loop
phosphorylation, and presumably independently of
Src kinases. These observations suggest that cell ad-
hesion-dependent tyrosine phosphorylation of FAK
occurs in two phases. The ¢rst, autophosphorylation
phase, occurs in the absence of Src and results in the
tyrosine phosphorylation of FAK residue 397. The
second phase occurs following recruitment of Src
into complex with FAK and results in phosphoryla-
tion of FAK at other tyrosine residues leading to the
full activation of FAK and transmission of down-
stream signals.
3.2. How is Src activated after integrin stimulation?
Src is negatively regulated by phosphorylation of a
C-terminal tyrosine residue by the Csk tyrosine ki-
nase [78]. This modi¢cation promotes an intramolec-
ular interaction between the C-terminus of Src and
its SH2 domain and a second intramolecular inter-
action involving the SH3 domain [78]. These intra-
molecular interactions stabilize Src in an inactive
conformation. Two major mechanisms of Src activa-
tion can be envisioned. First, dephosphorylation of
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the negative regulatory site could activate Src and
second activation could be achieved by disruption
of the low a⁄nity intramolecular SH2 and SH3 in-
teractions by the presentation of high a⁄nity ligands
for these binding sites. Both mechanisms have been
proposed for the activation of Src following engage-
ment of integrins by their ligands.
There are a number of ligands for the SH2 and
SH3 domains of Src in focal adhesions. The major
autophosphorylation site of FAK and a tyrosine
phosphorylation site on p130cas are Src SH2 domain
ligands [9,79]. In addition, there are Src SH3 domain
binding sites in paxillin, p130cas and FAK [77,79,80].
In both FAK and p130cas, the docking sites for the
Src SH2 and SH3 domains are near one another
suggesting that both domains of Src may be simulta-
neously engaged. Src can be potently activated by
disruption of both of its intramolecular inhibitory
interactions by competition with the SH3 domain
and SH2 domain binding sites from either FAK or
a p130cas-related protein, Sin1 [77,81]. Thus this
mechanism of activation following tyrosine phos-
phorylation of FAK and p130cas seems plausible.
This mechanism is unlikely to account for the acti-
vation of Src following stimulation of Swiss 3T3 cells
with neuropeptides, since cytochalasin D treatment,
which abrogates FAK tyrosine phosphorylation, has
no e¡ect upon Src activation [82]. In contrast to this
observation, cytochalasin D treatment of NIH 3T3
partially inhibits Src activation in response to cell
adhesion [65]. This ¢nding demonstrates that Src
can be activated independently of FAK but also sug-
gests that a FAK-dependent pathway is required for
maximal stimulation of Src activity following cell
adhesion.
There is also evidence that tyrosine phosphatases
may function in the activation of Src following cell
adhesion. Overexpression of a catalytically inactive
mutant of PTP1B in L cells inhibits cell spreading
and reduces cell adhesion-dependent tyrosine phos-
phorylation [83]. Src exhibits lower activity in these
cells suggesting that the mutant PTP1B may inhibit
the endogenous wild-type PTP1B and block Src ac-
tivation [83]. In these cells there is a small amount of
PTP1B that can be coimmunoprecipitated with L1
integrin and a small amount of PTP1B may localize
to focal adhesions [83]. Shp2 might also function in
the regulation of Src following cell adhesion. Shp23/
3 ¢broblasts exhibit reduced spreading on ¢bronec-
tin and reduced activation of Src upon adhesion to
¢bronectin [84]. Thus Shp2 is also a candidate as the
regulatory phosphatase that activates Src upon cell
adhesion. While these initial studies support the role
of PTP1B and Shp-2 in the activation of Src follow-
ing cell adhesion, further analyses are required to
¢rmly establish these functions. In contrast, there
are a number of studies strongly suggesting that
PTPK may serve to activate Src following cell adhe-
sion.
PTPK might function as a positive regulator of Src
since overexpression of PTPK activates Src in vivo
and induces cellular transformation [85,86]. Several
recent reports have begun to assess the role of PTPK
in the regulation of Src activity following cell adhe-
sion. Overexpression of wild-type PTPK in A431 cells
induces dephosphorylation of Src and an elevation in
the catalytic activity of Src [87]. PTPK expression
also promotes assembly of a complex between
FAK and Src, a complex that normally forms in
response to integrin-dependent cell adhesion, and
promotes tyrosine phosphorylation of paxillin, a fo-
cal adhesion-associated protein [87]. Exogenously ex-
pressed PTPK mutants were shown to localize to
focal adhesions in NIH 3T3 cells, and thus PTPK
might localize to sites of integrin signaling [88].
PTPK3/3 ¢broblasts were recently derived and
shown to have reduced Src family kinase activity
and exhibit a delay in spreading, a defect that is
shared with Src de¢cient cells [89]. Some insight
into the mechanism of regulation of Src by PTPK
has recently been obtained. A C-terminal tyrosine
in PTPK is a site of phosphorylation and appears
to serve as a docking site for the SH2 domain of
Src [90]. This interaction might disrupt the intramo-
lecular inhibitory interactions within Src exposing
the C-terminal regulatory phosphotyrosine residue
for dephosphorylation, in addition to recruiting Src
into complex with the phosphatase.
The evidence described suggests that FAK can be-
come autophosphorylated initially in the absence of
Src (Fig. 4, models A and C). While Src might be
activated by complex formation with FAK and dis-
ruption of intramolecular inhibitory interactions, this
mode of activation is not likely the major mechanism
of Src activation (Fig. 4, model A). The actions of
protein tyrosine phosphatases, currently the odds-on
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favorite being PTPK, seem to activate Src in response
to cell adhesion (Fig. 4, models B and C). Once FAK
and Src are independently activated, complex forma-
tion occurs. This may help stabilize Src in its active
conformation. In addition Src catalyzes tyrosine
phosphorylation of FAK on additional residues, el-
evating the kinase activity of FAK, creating binding
sites for other signaling molecules and promoting the
transmission of downstream signals.
4. Inhibition of FAK signaling
4.1. FIP200: a negative regulator of FAK?
A new binding partner that may be involved in
negative regulation of FAK signaling was recently
isolated [91]. The protein, FIP200, was isolated
from a yeast two-hybrid screen using the N-terminal
and catalytic domains of CAKL as bait. The FIP200
binding site was mapped to the catalytic domain of
CAKL, and FIP200 can inhibit the catalytic activity
of CAKL in vitro and block CAKL signaling in vivo.
FIP200 was also shown to bind to FAK and to in-
hibit the catalytic activity of FAK in vitro. Thus this
protein may be involved in regulating both members
of the FAK family of tyrosine kinases.
4.2. FAK and protein tyrosine phosphatases
Since tyrosine phosphorylation of FAK regulates
its catalytic activity and association with other sig-
naling molecules, dephosphorylation of tyrosine res-
idues is potentially a very important mechanism in
regulating FAK signaling. A number of tyrosine
phosphatases have been suggested as regulators
of FAK, including PTP-PEST [92] and PTP1B
[93]. However, there is more compelling evidence
that Shp-2 might regulate FAK tyrosine phosphory-
lation, and the most convincing evidence to date
suggests that PTEN catalyzes dephosphorylation of
FAK.
The SH2 domain containing tyrosine phosphatase,
Shp-2, has been proposed to regulate tyrosine phos-
phorylation of FAK in multiple scenarios, although
the regulation of FAK by Shp-2 may be complicated.
Several receptor tyrosine kinases have been reported
to reduce tyrosine phosphorylation of FAK, includ-
ing the insulin receptor, IGF-1R and EphA2 [39,40].
The IGF-1R and EphA2 can coimmunoprecipitate
with both FAK and Shp-2 and overexpression of a
catalytically inactive Shp-2 mutant in MCF-7 cells
can block dephosphorylation of endogenous FAK
in response to IGF-1 [39]. In contrast, PDGF stim-
ulation of porcine aortic endothelial cells induces ac-
tivation of FAK and a PDGF receptor mutant that
cannot bind to Shp-2 fails to induce FAK activation
in response to PDGF [94]. Thus Shp-2 has been pro-
posed to inhibit signaling by promoting FAK de-
Fig. 4. Models of Src and FAK activation. In suspended cells
Src is inactive (1) and FAK is in its dephosphorylated state (2).
Three possible models for the activation of these kinases and
assembly into a signaling complex can be proposed. (A) FAK
clustering might be su⁄cient to induce transphosphorylation at
tyrosine 397 (3). The inactive Src protein might be recruited
into complex with FAK, with the high a⁄nity SH2 and SH3
binding sites in FAK disrupting the intramolecular inhibitory
interactions in Src, resulting in the activation of Src and assem-
bly of the FAK/Src signaling complex (9). (B) Src might be ini-
tially activated by a phosphatase (4). Activated Src could phos-
phorylate FAK on the activation loop residues (5), activating
FAK and promoting autophosphorylation at tyrosine 397 (6).
Activated Src could then be recruited into complex with acti-
vated FAK to form a signaling complex (9). (C) Src and FAK
could independently be activated (7,8) and then activated Src
and FAK assembled into a signaling complex.
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phosphorylation and to activate FAK in response to
di¡erent stimuli.
Shp-2 may function in regulating FAK signaling
upon cell adhesion since Shp-2 de¢cient ¢broblasts
exhibit a defect in spreading and motility, which are
biological responses that are regulated by FAK
[84,95]. However, further experimentation to de¢ne
the biochemical consequences of altering Shp-2 func-
tion has not yielded consistent results. In one in-
stance, tyrosine dephosphorylation of FAK was re-
portedly impaired when Shp-2-de¢cient cells were
taken into suspension, suggesting that Shp-2 might
function in dephosphorylating FAK upon de-adhe-
sion from the extracellular matrix [95]. A second re-
port describes impaired tyrosine phosphorylation of
FAK upon adhesion of Shp-2-de¢cient cells to the
extracellular matrix suggesting the Shp-2 promotes
tyrosine phosphorylation of FAK [84]. This defect
in FAK tyrosine phosphorylation upon cell adhesion
is ascribed to a defect in activation of Src. In a third
study, expression of a catalytically defective Shp-2
mutant in Rat-1 cells, which might be expected to
exhibit the same e¡ect as the Shp-2 de¢ciency, has
no e¡ect upon FAK phosphorylation when cells are
taken into suspension and shows an increase in FAK
tyrosine phosphorylation when cells are plated on
¢bronectin [96]. While Shp-2 is intriguing as a can-
didate regulatory phosphatase for FAK, no consis-
tent theme regarding the e¡ects of Shp-2 upon FAK
has yet emerged from these investigations, making it
di⁄cult to de¢nitively assign a function for Shp-2 in
regulating FAK dephosphorylation.
The strongest evidence to date suggests that PTEN
may catalyze dephosphorylation of FAK. This is a
very intriguing hypothesis since PTEN was originally
isolated as a tumor suppressor gene, which may have
implications for FAK in the development of cancer
[97,98]. PTEN exhibits three di¡erent types of phos-
phatase activity. Originally shown to be a protein
tyrosine phosphatase, PTEN was later shown to
also exhibit serine/threonine phosphatase activity in
vitro and most recently to function as a lipid phos-
phatase [99^101]. The lipid phosphatase activity of
PTEN is directed against phosphatidyl-inositols con-
taining phosphate at the D3 position. Consequently,
PTEN functions to degrade the reaction product of
PI3-kinase and was shown to function as a negative
regulator of PI3-kinase signaling in vivo [102].
There are several lines of evidence implicating
PTEN in the regulation of tyrosine phosphorylation
of FAK. Overexpression of PTEN in either NIH 3T3
cells or U87-MG cells, which are PTEN de¢cient,
causes a reduction in tyrosine phosphorylation of
FAK [103^105]. Expression of a catalytically defec-
tive mutant of PTEN induces a small increase in ty-
rosine phosphorylation of FAK and the mutant
PTEN protein coimmunoprecipitates with FAK
[103,105]. Interestingly, catalytically defective PTEN
variants do not associate with a FAK mutant con-
taining a phenylalanine for tyrosine substitution at
residue 397 (the major autophosphorylation site of
FAK), suggesting that PTEN may target this impor-
tant phosphorylation site for dephosphorylation
[105]. Further, in an in vitro assay, recombinant
PTEN can dephosphorylate FAK protein that has
been subjected to sodium dodecyl sulfate^polyacryl-
amide gel electrophoresis, transferred and immobi-
lized to a membrane [103]. Expression of PTEN in
NIH 3T3 cells or U87-MG cells induces a number of
phenotypic changes that are similar to phenotypes
associated with inhibition of FAK signaling, includ-
ing reduced spreading, motility and invasion
[103,104]. Simultaneous overexpression of FAK
with PTEN reverted these phenotypes consistent
with the hypothesis that PTEN induced these pheno-
types by dephosphorylation of FAK and inhibition
of FAK signaling. Although these experiments sug-
gest that FAK is a PTEN substrate, other studies
have failed to provide similar evidence. Analysis of
PTEN3/3 ES cells and ¢broblasts revealed no in-
crease in tyrosine phosphorylation of FAK, contrary
to the predicted result if FAK was a major PTEN
substrate [106,107]. In addition, overexpression of
PTEN in U87MG cells does not always lead to
FAK dephosphorylation [108].
The activity of PTEN as a protein phosphatase has
received much less scrutiny than its role as a lipid
phosphatase. One speci¢c PTEN mutation that is
associated with human disease, G129E, abrogates
lipid phosphatase activity, but has little e¡ect upon
its protein phosphatase activity [99]. This ¢nding
suggests that the lipid phosphatase activity of
PTEN is essential in its role as a tumor suppressor.
In support of this hypothesis, wild-type PTEN res-
cues a number of cellular phenotypes exhibited by
cancer cells containing PTEN lesions, whereas the
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G129E mutant does not [102,109]. However, these
experiments demonstrate the importance of lipid
phosphatase activity without assessing the role of
protein phosphatase activity. In fact, the G129E var-
iant of PTEN functions as well as the wild-type
PTEN to inhibit cell spreading and invasion of
U87-MG cells, demonstrating that PTEN exhibits
some biological activity in the absence of lipid phos-
phatase activity [103,104]. Further investigation of
PTEN is clearly required to fully de¢ne the role of
its protein phosphatase activity in tumor suppression
and the role of PTEN in regulating tyrosine phos-
phorylation of FAK. It is interesting to note that one
downstream e¡ector of FAK signaling is PI3-kinase.
PTEN may utilize its protein phosphatase activity to
dephosphorylate FAK, thus inhibiting the activation
of PI3-kinase, and its lipid phosphatase activity to
degrade any products of PI3-kinase that are gener-
ated (Fig. 5). In this fashion PTEN could serve as a
very potent inhibitor of PI3-kinase signaling follow-
ing integrin-dependent cell adhesion.
Although there are clearly some provocative can-
didate protein tyrosine phosphatases that may cata-
lyze dephosphorylation of FAK, this aspect of FAK
regulation is only beginning to be elucidated. The
fact that multiple tyrosine residues of FAK are phos-
phorylated raises the possibility that distinct protein
tyrosine phosphatases may be responsible for de-
phosphorylation of di¡erent sites. Since di¡erent
phosphorylation sites function to regulate catalytic
activity and protein^protein interactions, site-speci¢c
dephosphorylation of FAK may be an e¡ective
mechanism to modulate some aspects of FAK signal-
ing independently from others. The study of tyrosine
dephosphorylation of FAK will undoubtedly provide
an area of fruitful investigation in the near future.
4.3. Proteolytic cleavage of FAK
While dephosphorylation of FAK may function to
curb signaling, an equally e¡ective, albeit more dra-
matic, mechanism of terminating FAK signaling is
proteolytic cleavage. Proteolysis of FAK was ¢rst
observed in chicken embryo ¢broblasts transformed
by the v-src or myc oncogenes [110,111]. Cleavage of
FAK was subsequently observed in a number of oth-
er cell types exposed to di¡erent stimuli [112^117]. In
each of these experimental systems FAK is similarly
cleaved into a large N-terminal fragment of 85^100
kDa that is subsequently cleaved into smaller frag-
ments and a C-terminal fragment of approximately
35 kDa. Through the use of pharmacological inhib-
itors and in vitro cleavage assays, several proteases
have been implicated in FAK cleavage. Caspases 3
and 7 have been identi¢ed as major enzymes involved
in cleavage of FAK, whereas caspase 6 might play a
minor role [112,113,118]. In other situations calpain
has been implicated as the protease responsible for
FAK cleavage [114,115,119].
The major caspase 3 cleavage site has been identi-
¢ed as a DQTDS sequence beginning at amino acid
772 in FAK [118]. However, this cleavage site is not
highly conserved amongst vertebrate FAK sequences
and is more divergent in the sequence of Drosophila
FAK. Although this site is not conserved in murine
FAK, apoptotic stimuli still induce proteolytic cleav-
age of FAK in mouse cells to generate fragments
similar, but not identical, in size to the fragments
generated in human cells [118]. It is striking that
di¡erent proteases are induced by di¡erent stimuli
to cleave FAK generating similar proteolytic frag-
ments. It is of further interest to note that FAK
cleavage occurs in di¡erent species, yet the one pro-
Fig. 5. PTEN regulation of FAK and PI3-kinase signaling. Au-
tophosphorylation of FAK promotes complex formation with
PI3-kinase, which likely results in the generation of PI3-phos-
phates in the membrane. PTEN can dephosphorylate FAK to
block association with PI3-kinase. PTEN can also dephosphory-
late PI3-phosphates to terminate signaling downstream of PI3-
kinase. Thus PTEN might intervene at two positions within this
signaling cascade.
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tease cleavage site that has been mapped is not evo-
lutionarily conserved. Perhaps the target site for
cleavage by these various proteases is a region of
FAK that is exposed and particularly susceptible to
cleavage.
What are the consequences of FAK cleavage? The
major site of cleavage of FAK in response to these
stimuli separates the catalytic domain of FAK from
the FAT sequence. The enzyme activity of cleaved
FAK would be mislocalized and therefore ine¡ective
at transmitting signals. The more interesting possibil-
ity, that the cleavage fragments of FAK might ac-
tively transmit aberrant signals that promote cell
cycle arrest or induce apoptosis has also been sug-
gested. Overexpression of a C-terminal FAK frag-
ment, similar to the C-terminal product of cleavage,
can induce apoptosis and overexpression of a FAK
mutant that fails to localize to focal adhesions can
inhibit cell cycle progression [49,50] [120]. Whether
cleavage of endogenous FAK simply terminates sig-
naling or generates fragments that actively promote
cell death remains to be established.
5. FAK signaling
As outlined in the overview, there are a number of
biochemical pathways that can be activated down-
stream of FAK. These include signaling components
that are well known from the ¢eld of growth factor
receptor signaling; the PI3-kinase, PLCQ and MAP
kinase pathways. FAK can also transmit down-
stream signals by tyrosine phosphorylation of
FAK-associated adaptor proteins, paxillin and
p130cas, which in turn recruit additional signaling
molecules into complex resulting in activation of
downstream pathways. These signaling pathways
have been reviewed both in the context of FAK sig-
naling and otherwise and will not be extensively dis-
cussed here [1,121^125]. However, recent ¢ndings
regarding FAK signaling and the MAP kinase
pathway merit some discussion.
5.1. FAK and MAP kinases
Several mechanisms can be utilized by FAK to
stimulate MAP kinase signaling. FAK can be phos-
phorylated on tyrosine 925 to create a Grb2 binding
site and recruitment of a Grb2/SOS complex is one
mechanism that FAK may use to activate Ras and
the MAP kinase pathway [11]. FAK contains a bind-
ing site for the p130cas adaptor protein and tyrosine
phosphorylation of p130cas can result in the recruit-
ment of the Crk and Nck adaptor proteins. Since
these adaptor proteins can bind SOS, this provides
a second mechanism for stimulation of Ras/MAP
kinase signaling [73]. Finally, FAK activation can
promote tyrosine phosphorylation of Shc, which in
turn recruits Grb2 and SOS into complex promoting
the activation of Ras and the MAP kinase pathway
[44]. Thus there are apparently multiple mechanisms
that FAK could employ to induce the activation of
MAP kinase (see Fig. 6).
The role of FAK in the activation of MAP kinase
in response to integrin engagement has been contro-
versial. Clearly there are other signaling pathways
that integrins can utilize to induce activation of
MAP kinase, since MAP kinase activation can be
dissociated from tyrosine phosphorylation of FAK
[126^128]. On the other hand, the expression of
FAK can enhance cell adhesion-dependent activation
of MAP kinase and it has been reported that inhibi-
tion of FAK signaling blocks MAP kinase activation
in response to integrin-dependent signaling in epithe-
lial cells [1,129]. These con£icting reports suggest
that under certain conditions FAK is a major regu-
lator of MAP kinase activation following integrin
stimulation, whereas under other conditions other
signaling pathways to MAP kinase are dominant.
One interesting suggestion is that the expression of
B-Raf might be the key di¡erence between these in-
dividual experiments [128]. It was proposed that
FAK signaling via p130cas/Crk/C3G leads to the ac-
tivation of Rap1, B-Raf, MEK and ¢nally MAP ki-
nase in cells expressing B-Raf [128]. However, in cells
lacking B-Raf this signaling pathway is inoperative,
and other mechanisms for the activation of MAP
kinase are employed. It was further proposed that
FAK induced MAP kinase activation was a later
event in integrin signaling. Thus activation of
FAK-independent MAP kinase activation pathways
would produce a transient activation and the addi-
tional engagement of the FAK-dependent pathway
would produce a prolonged MAP kinase response.
According to this theory, FAK might play an impor-
tant role in controlling the kinetics of MAP kinase
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activation, which might have a profound e¡ect upon
the ultimate biological response to the signal.
In addition to activation of the MAP kinase path-
way, there is some indication that integrin-dependent
adhesion causes activation of the JNK pathway, and
that FAK might play a role in this pathway as well
[130^132]. FAK may utilize di¡erent mechanisms to
activate MAP kinase and JNK since a catalytically
inactive FAK mutant fails to activate MAP kinase,
but still activates JNK [131]. In this system, using an
activated, membrane-bound FAK construct, the
linkage to JNK was proposed to occur via recruit-
ment of paxillin, and an associated exchange factor
for Rho family proteins, into complex with FAK.
This mechanism of JNK activation occurs indepen-
dently of tyrosine phosphorylation. There are also
other phosphotyrosine-dependent mechanisms that
FAK could use to stimulate the JNK pathway,
e.g., via p130cas/Crk/Dock180 and stimulation of
Rac [50]. Further experimentation is required to de-
¢ne the mechanisms that FAK might utilize to stim-
ulate JNK activity in response to integrin engage-
ment.
The role of FAK in regulating MAP kinases dis-
cussed in the above paragraphs relates to MAP ki-
nase activation in response to integrin-dependent cell
adhesion. One other interesting aspect of integrin
signaling is the synergistic activation of the MAP
kinase signaling pathway when both the integrins
and growth factor receptors are simultaneously
stimulated [133,134]. Recent evidence suggests that
FAK may function in the crosstalk between these
two receptor classes. Expression of a CD2/FAK chi-
mera that is constitutively active can substitute for
integrin-dependent adhesion and promote maximal
MAP kinase activation in response to PDGF [48].
Further, fak3/3 cells exhibit a defect in PDGF-
and serum-induced MAP kinase activation and over-
expression of dominant negative mutants of FAK in
NIH3T3 cells blocks serum induced activation of
MAP kinase [48,135]. FAK has also been implicated
in the activation of MAP kinase following stimula-
Fig. 6. Multiple FAK signaling pathways can converge on MAP kinase and JNK. Several pathways are proposed to link FAK to the
activation of MAP Kinase. (1) The C-terminus of FAK contains a binding site that can recruit Grb2/SOS. (2) Tyrosine phosphoryla-
tion of Shc can be induced by FAK leading to the assembly of a Shc/Grb2/SOS complex. (3) p130cas, which associates with FAK, be-
comes tyrosine phosphorylated, creating binding sites for the Crk and Nck adaptor proteins. This promotes recruitment of Nck/SOS
and Crk/C3G complexes. The SOS and C3G exchange factors can activate GTP-binding proteins leading to activation of MAP ki-
nase. Multiple pathways also lead to JNK signaling. Tyrosine phosphorylation of p130cas can also recruit Crk/Dock 180 complexes
that may signal through Rac to activate JNK. A phosphotyrosine independent linkage to JNK, via the paxillin/PKL/PIX complex has
also been proposed.
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tion of the urokinase-type plasminogen activator re-
ceptor [136]. One other interesting observation is that
inhibition of FAK signaling by a dominant negative
variant has a major e¡ect upon the duration of MAP
kinase activation following PDGF stimulation of
smooth muscle cells [135]. Inhibition of FAK in
this case produced a transient activation of MAP
kinase following PDGF stimulation, rather than the
more prolonged response seen in control cells. This
observation is interesting in light of the previous
proposition that FAK might control the temporal
response of MAP kinase induced by integrin signal-
ing. In contrast to the evidence provided in these
studies, one other report disputes the role of FAK
in the activation of MAP kinase in response to
PDGF in ¢broblasts [128]. Thus, this e¡ect may
also exhibit a cell type dependency. The cells utilized
in this latter analysis also do not require FAK for
the stimulation of MAP kinase in response to integ-
rin-dependent cell adhesion.
Although the controversy regarding the role of
FAK in MAP kinase activation remains to be re-
solved, two of these recent ¢ndings are particularly
intriguing. First, FAK may function to coordinate
MAP kinase signaling following costimulation of in-
tegrins and growth factor receptors. Second, FAK
may control the temporal response of MAP kinase
to stimuli. These ¢ndings suggest that FAK may play
a somewhat unique function in controlling MAP ki-
nase stimulation.
6. Biological responses to FAK signals
6.1. FAK, Rho and the regulation of focal adhesion
turnover
Hypotheses about the role of FAK in focal adhe-
sion assembly/disassembly have dramatically
changed over the years. FAK was originally thought
to function in the assembly of focal adhesions. How-
ever, a study performed using v-src transformed ¢-
broblasts suggested that FAK might perform the op-
posite function, i.e., promote the disassembly of focal
adhesions [110]. This theory was partially corrobo-
rated with studies using fak3/3 ¢broblasts, since
these cells exhibit larger focal adhesions than the
control FAK expressing ¢broblasts [5]. This hypoth-
esis has now been very elegantly con¢rmed by imag-
ing a GFP-K-actinin chimeric protein in spreading
cells [137]. In spreading, control ¢broblasts, GFP-
K-actinin assembles into focal adhesions which then
undergo disassembly. In contrast, in spreading fak3/
3 cells, GFP-K-actinin assembles into focal adhe-
sions, which remain intact for the duration of the
experiment [137]. These results provide very strong
support for FAK as a regulator of disassembly of
focal adhesions.
The intriguing possibility that FAK may control
focal adhesion disassembly by downregulating Rho
activity has been proposed [137]. Whereas ¢broblasts
exhibit a transient reduction in the activity of Rho
upon adhesion to ¢bronectin, fak3/3 ¢broblasts ex-
hibit no reduction in Rho activity [71,137]. Since
Rho activity is important for FAK activation, this
may be a negative feedback mechanism to inhibit
Rho signaling (see Fig. 7). Further the morphological
di¡erences observed between wild-type and fak3/3
Fig. 7. FAK and Rho; interdependent regulation. Rho is active
when bound to GTP and inactive in its GDP bound form. Ex-
change factors promote GTP binding to Rho, which induces
contractility. This induces assembly of stress ¢bers and focal
adhesions, promoting tyrosine phosphorylation of FAK. FAK
binds a GTPase activating protein (GAP), called GRAF, which
may promote hydrolysis of GTP bound to Rho. FAK and Src
have both been implicated in inhibiting Rho activity upon cell
adhesion. There is also evidence that a second GAP, RhoGAP,
functions in inhibiting Rho following cell adhesion.
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¢broblasts, including the characteristic appearances
of their focal adhesions, are apparently due to di¡er-
ent levels of Rho activity. Inhibition of Rho causes
fak3/3 cells to resemble wild-type ¢broblasts,
whereas introduction of an activated Rho construct
into normal ¢broblasts induces a morphology resem-
bling fak3/3 cells [137]. These data suggest that
FAK regulates focal adhesion turnover by modulat-
ing Rho activity.
The mechanism by which FAK inhibits Rho sig-
naling has not been addressed, but could involve the
FAK-binding partner GRAF, a negative inhibitor of
Rho [12]. In an interesting parallel study, the Src
family of tyrosine kinases has been implicated in
the inhibition of Rho activity upon engagement of
integrins [138]. The results of this study further sug-
gest that RhoGAP may play a role in inhibiting the
activity of Rho upon adhesion to ¢bronectin [138].
The results of the two studies together might suggest
a role for the FAK/Src complex in the feedback to
inhibit Rho activation, an experimentally testable hy-
pothesis using a reconstitution approach in fak3/3
cells.
6.2. FAK and cell motility
Earlier experiments demonstrated that FAK sig-
naling regulates the motility of cells in response to
an extracellular matrix protein stimulus, a process
called haptotaxis [5,8]. More recent experiments
have focused upon identi¢cation of FAK-regulated
signaling pathways that may be involved in control-
ling motility. The major autophosphorylation site of
FAK, tyrosine 397, is absolutely required for enhanc-
ing cell motility [8,139,140]. The original interpreta-
tion of this observation was that Src recruitment into
complex with FAK was required for cell motility.
However, the discovery that the SH2 domains of
additional signaling molecules also directly associate
with the autophosphorylation site of FAK has forced
reconsideration of this conclusion. In support of a
role for Src, transient expression of exogenous
FAK in fak3/3 ¢broblasts enhanced cell motility,
whereas coexpression of the Src inhibitory kinase,
Csk, reduced the ability of FAK to promote cell
migration [140]. A likely downstream target for
FAK/Src tyrosine phosphorylation in the cell migra-
tion pathway is p130cas. This FAK-associated pro-
tein is tyrosine phosphorylated following cell adhe-
sion and has independently been implicated in cell
motility [141]. A FAK mutant, defective for binding
p130cas fails to induce tyrosine phosphorylation of
p130cas and is also defective for inducing cell migra-
tion [140,142]. Furthermore, overexpression of a
fragment of p130cas, predicted to function as a dom-
inant negative mutant and inhibit the recruitment of
endogenous p130cas to FAK, impairs FAK-depen-
dent cell migration [142]. These observations support
a role for Src and p130cas in the promotion of cell
motility by FAK.
Additional studies have identi¢ed other FAK-
binding partners that also may function in regulating
cell motility. A mutant of FAK that retains binding
to the Src SH2 domain, but fails to associate with the
PI3-kinase SH2 domain fails to stimulate motility
when overexpressed in CHO cells [42]. This experi-
ment identi¢es PI3-kinase as an e¡ector of FAK that
functions in the regulation of motility.
Grb7 is also a good candidate as a regulator of
motility since it can bind FAK, is tyrosine phosphor-
ylated in a FAK dependent manner and has been
implicated in the regulation of motility [43,143].
However, its linkage to FAK-dependent motility
has not been completely solidi¢ed, since Grb7 mu-
tants can inhibit motility in fak3/3 cells. Additional
experimental evidence, as was obtained for the role
of Src and PI3-kinase in FAK-dependent motility, is
required to absolutely place Grb7 in a pathway
downstream of FAK in the regulation of migration.
In addition to haptotactic motility, cells also ex-
hibit chemotactic motility in response to extracellular
stimuli like growth factors. Recent studies have also
implicated FAK in controlling chemotactic responses
in cells. Overexpression of FAK in MDCK cells in-
creases the ability of these cells to ‘scatter’ in re-
sponse to HGF [144]. In addition, FAK overexpres-
sion enhances the motility of MDCK cells in
response to HGF in a chemotaxis assay [144]. Uro-
kinase-type plasminogen activator stimulates motility
of MCF-7 cells and inhibition of FAK signaling us-
ing a dominant negative approach inhibits the che-
motactic response of the cells [136]. Fak3/3 ¢bro-
blasts exhibit defective chemotactic responses to
PDGF and EGF. Re-expression of FAK in these
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cells restores the chemotactic response in these cells
[36]. Thus in several di¡erent chemotactic systems,
FAK has been implicated as a regulatory protein.
The mechanism(s) by which FAK controls chemo-
taxis has not been fully elucidated. Some experimen-
tal data suggests that similar FAK pathways are in-
volved in the response to HGF induced chemotaxis
and to haptotaxis in MDCK cells [144]. In particular,
the PI3-kinase and p130cas pathways have been im-
plicated in chemotaxis since FAK mutants that do
not engage these e¡ectors fail to promote chemotaxis
[144]. In contrast, FAK may function di¡erently in
the chemotactic response to EGF and PDGF in ¢-
broblasts [36]. The autophosphorylation site of FAK
is required to promote chemotaxis and recruitment
of Src into complex also appears necessary since
FAK-dependent chemotactic responses are blocked
by overexpression of Csk [36]. However, FAK mu-
tants that fail to bind to p130cas or Grb2 are as
e¡ective as wild-type FAK at promoting chemotaxis
[36]. Both the N-terminal and C-terminal domains of
FAK are required for FAK to promote chemotaxis
in fak3/3 cells. Unexpectedly, the N-terminal do-
main of FAK, including the major autophosphory-
lation site, will support some of FAK’s function in
chemotaxis [36]. Presumably this fragment becomes
tyrosine phosphorylated and recruits signaling mole-
cules to ful¢ll these functions. While these studies
demonstrate that FAK can function to promote che-
motaxis, in addition to its well established role in
haptotaxis, there are many discrepancies regarding
the mechanisms involved that remain to be resolved
before we understand how FAK may control chemo-
taxis.
6.3. FAK and the cell cycle
FAK has also been proposed to function as a pos-
itive regulator of the cell cycle. Overexpression of
FAK can modestly enhance DNA synthesis in ¢bro-
blasts after the cells have been starved and stimu-
lated with serum [120,145]. Conversely, mutants of
FAK can function in a dominant negative fashion
to inhibit progression through the cell cycle following
serum stimulation [120,130]. While the mechanism of
FAK function in controlling cell cycle progression
has not been completely elucidated, there is some
evidence that FAK may function to control the levels
of cyclin D and the cyclin-dependent kinase inhibi-
tor, p21 [120].
6.4. FAK and apoptosis
In many cells, the extracellular matrix transmits a
cell survival signal. When cells are cultured in the
absence of this survival signal, they undergo apopto-
sis or anoikis [146]. Inhibition of FAK can induce
apoptosis and overexpression of FAK can prevent
anoikis and apoptosis induced in response to other
stimuli [6,7,49,50,117,147^149]. These ¢ndings sup-
port the role of FAK in transmitting a cell survival
signal.
Several approaches have been taken to begin to
elucidate the mechanism(s) of action of FAK in pro-
moting cell survival. FAK mutants were utilized to
demonstrate that the catalytic activity of FAK and
the major autophosphorylation site of FAK (tyrosine
397) were required to protect cells from apoptosis
[7,117,149]. In MDCK cells, the association of
FAK with PI3-kinase was speci¢cally shown to be
a prerequisite for the inhibition of apoptosis induced
by ultraviolet light [117]. In HL60 cells, tyrosine 925,
which binds Grb2 and links FAK to the Ras/MAPK
pathway, was also required to inhibit apoptosis [149].
Additional insights into the mechanism by which
FAK regulates apoptosis come from experiments us-
ing dominant negative FAK constructs to inhibit en-
dogenous FAK signaling. Overexpression of a GFP
fusion protein containing just the C-terminal FAT
sequence of FAK induced apoptosis in rabbit syno-
vial ¢broblasts, whereas overexpression of a GFP-
FRNK fusion protein did not [49,50]. Further anal-
ysis using mutants of FAK and FRNK demon-
strated that the p130cas binding site was required to
prevent apoptosis of ¢broblasts in the absence of
serum [50]. Additional evidence suggested that
FAK could activate JNK through recruitment and
tyrosine phosphorylation of p130cas that in turn sig-
nals to Rac, Pak1 and MKK4 to stimulate JNK
activity [50]. In this system expression of activated
Akt failed to block apoptosis induced by the FAT
construct suggesting that the PI3-kinase signaling
alone was insu⁄cient to block apoptosis [49,50].
An alternative mechanism for the inhibition of apo-
ptosis by FAK was demonstrated in HL60 cells.
FAK overexpression appeared to enhance NFUB ac-
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tivity and stimulate expression of cIAP-1, cIAP-2
and X-IAP, which are endogenous inhibitors of cas-
pases and thus potent inhibitors of apoptosis
[149,150].
The described studies have demonstrated that
FAK functions to promote cell survival in response
to cell adhesion. Interestingly, some studies suggest
that overexpression of FAK can protect cells from
apoptosis in response to other stimuli. Some progress
has been made toward de¢ning the mechanism(s)
utilized by FAK to prevent cell death, although
they remain to be fully elucidated. This information
could be important for the design of strategies to
inhibit FAK-promoted cell survival in experimental
and pathological scenarios.
6.5. FAK and cancer
FAK was isolated as a tyrosine phosphorylated
substrate from cells transformed by the v-src onco-
gene [151]. The ¢nding that Src signaling is activated
in a number of human tumors suggests that any role
for FAK in this system might be relevant to human
disease and not restricted to model systems for trans-
formation [152]. FAK may function to promote
maximal tyrosine phosphorylation of some sub-
strates, like paxillin, and stimulate MAP kinase acti-
vation in transformed cells [48,53]. However, inhibi-
tion of FAK using dominant negative mutants has
no e¡ect upon the phenotype of v-src-transformed
cells [48,75].
FAK might also function downstream of integrins
in some cancers since changes in the repertoire of
integrins on the surface of cells can profoundly
change the cancerous phenotype of cells [153^155].
Some of these changes are likely to occur due to
altered signaling in these cells. FAK has not been
directly implicated as a component of an altered in-
tegrin signaling pathway in transformed cells, but
remains an attractive candidate.
Expression of a constitutively active, membrane-
bound FAK chimera (CD2/FAK) in several cell
types has elicited some of the phenotypes of cancer.
MDCK cells expressing CD2/FAK have acquired the
ability to grow in soft agar and form tumors in nude
mice [7]. NIH3T3 cells expressing this construct have
also been analyzed. Although CD2/FAK could not
promote the growth of NIH3T3 cells in soft agar,
nor increase the number of colonies that Ras-trans-
formed NIH3T3 cells form in soft agar, CD2/FAK
did induce an increase in the size of the colonies
formed by Ras-transformed NIH3T3 cells [48]. While
these studies are clearly just the ¢rst of many that
will attempt to prove in principle the role FAK
might play in the development of cancer, they estab-
lish that under certain circumstances, FAK signaling
can contribute to the development of some of the
phenotypes of cancerous cells.
FAK expression is elevated in a number of di¡er-
ent tumors including breast, colon, prostate, thyroid,
ovarian and mesenchymal tumors [156^161]. In some
cases, additional copies of the FAK gene have been
identi¢ed demonstrating that FAK overexpression
can sometimes be due to gene ampli¢cation [162].
Early analyses had suggested that FAK overexpres-
sion might be a late alteration in the development of
invasive and metastatic cancer. Further, in an in vi-
tro model for the development of colon cancer, FAK
ampli¢cation and overexpression was observed only
in the later stages of carcinoma development [163].
However, recent immunohistological analyses of
FAK expression in developing tumors has identi¢ed
populations of cells overexpressing FAK early in the
development of breast, colon and squamous cell car-
cinomas of the mouth [164,165]. In another study,
FAK was undetectable in primary ectocervical cells
or human foreskin ¢broblasts, but overexpressed in
these cells following immortalization by HPV or
SV40 large T antigen [166]. These results suggest
that FAK overexpression might be a very early event
in the progression of cancer. While these studies have
not irrefutably linked FAK to cancer, they certainly
present FAK as a compelling candidate as a regula-
tor of some aspects of tumor development and pro-
gression.
7. Concluding remarks
Recent studies have provided insight into the
mechanisms by which FAK signaling is regulated
and how FAK promotes cell motility and cell surviv-
al. Although our understanding of FAK signaling is
increasing, the picture is still far from clear. The role
of protein tyrosine phosphatases in inhibiting FAK
signaling is likely to be important and has not been
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fully explored. While some FAK signaling pathways
have been implicated in controlling biological pro-
cesses, other pathways remain to be tested. FAK is
potentially important in the pathology of human dis-
ease, e.g., cancer, but has not been de¢nitively linked
to the development of any disease. Although we have
come a long way in elucidating the biochemical and
biological functions of FAK, there is still much to be
learned before we fully understand the mechanisms
of FAK signaling.
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